A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment.
[More]
Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.
[More]
A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
[More]
A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS).
[More]
Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.
[More]
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept patch (once weekly donepezil HCl transdermal system).
[More]
According to new developments patients with advanced Alzheimer’s disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
[More]
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
[More]
The nicotine patch designed to help people quit smoking can also improve memory in older adults with mild cognitive impairment, or MCI, a small clinical trial found.
[More]
A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS one.
[More]
According to a new report sponsored by Alzheimer’s Disease International, nearly three-quarters of the 36 million people living with dementia have not been diagnosed with it. Experts say the lack of diagnosis has enormous repercussions on early treatment and care, and has a direct impact on the disease’s cost to society.
[More]
A ten-minute memory test that gives early warning of Alzheimer’s in people as young as 50 is being piloted in GP surgeries. Using a touch-screen computer or an iPad, it can distinguish between normal forgetfulness and the more dangerous memory lapses that signal dementia in its earliest stages. If trials are successful, it could be in widespread use in under a year. The developer, Cambridge Cognition, said the mobile electronic test will allow GPs to access patients presenting memory problems more quickly, simply and accurately than with tradition paper-based tests.
[More]
Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.
[More]
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.
[More]
Dr. Reddy's Laboratories today announced that it has launched three products in the US market.
[More]
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this product has commenced.
[More]
Actavis, an international generic pharmaceutical company, today announced that it has received approval from the US Food & Drug Administration to market Donepezil Hydrochloride Tablets a generic equivalent of Aricept®. Shipment will commence immediately.
[More]
Eisai announced today that the United States Food and Drug Administration issued a Complete Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application of the Aricept® Patch.
[More]
A devastating vascular disorder of the brain called CADASIL, which strikes young adults and leads to early dementia, often is misdiagnosed as multiple sclerosis, Loyola University Health System researchers report.
[More]
Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.
[More]